Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eargo, Inc.EAR · Entity 94112 | Chief Financial Officer | November 20, 2023 | November 22, 2023 |
| Twist Bioscience CorpTWST · Entity 3619 | Chief Financial Officer | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eargo, Inc.
Report date November 20, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 258 |
Reported balance
After 2023-11-20 transaction · row 1
1 source rowRow 1 · 2023-11-20 · Disposition to issuer · Disposed 33 · Balance 258 F1: This sale was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2023.
Twist Bioscience Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,114 |
Reported balance
After 2026-10-09 transaction · row 1
1 source rowRow 1 · 2026-10-09 · Sale · Disposed 2,462 · Balance 98,114 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,462 | $156.30 | $384,822.66 |
DisclosureSEC source: 0001214659-26-012823 · marketforms-74129.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,114 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 8,057 | $188.88 | $1,521,838.39 |
DisclosureSEC source: 0001214659-26-012549 · marketforms-74097.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,576 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 21, 2026 Filed Aug 25, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,965 | $139.07 | $273,264.69 |
DisclosureSEC source: 0001214659-26-010829 · marketforms-73879.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,633 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,399 | $94.33 | $226,307.27 |
DisclosureSEC source: 0001214659-26-008480 · marketforms-73600.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,276 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,000 | $70.00 | $280,000.00 |
DisclosureSEC source: 0001214659-26-007029 · marketforms-73321.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,675 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,019 | $53.26 | $107,525.88 |
DisclosureSEC source: 0001214659-26-006712 · marketforms-73244.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,675 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,000 | $60.00 | $240,000.00 |
DisclosureSEC source: 0001214659-26-004893 · marketforms-72950.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,694 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,000 | $55.00 | $165,000.00 |
DisclosureSEC source: 0001214659-26-004735 · marketforms-72938.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,694 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,597 | $49.89 | $129,561.73 |
DisclosureSEC source: 0001214659-26-004601 · marketforms-72923.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,694 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,085 | $46.71 | $97,389.93 |
DisclosureSEC source: 0001214659-26-002442 · marketforms-72310.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,291 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,000 | $50.00 | $350,000.00 |
DisclosureSEC source: 0001214659-26-001737 · marketforms-72137.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,031 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:13 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,000 | $40.00 | $120,000.00 |
DisclosureSEC source: 0001214659-26-000509 · marketforms-71849.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,031 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,738 | $35.26 | $96,544.62 |
DisclosureSEC source: 0001214659-26-000423 · marketforms-71821.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,031 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 887 | $26.50 | $23,508.60 |
DisclosureSEC source: 0001214659-25-017219 · marketforms-71345.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,769 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 32,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017001 · marketforms-71305.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,656 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,517 | $31.44 | $173,478.20 |
DisclosureSEC source: 0001214659-25-015763 · marketforms-71186.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,008 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-015583 · marketforms-71172.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,525 F1 · shares: Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,517 | $32.92 | $82,864.67 |
DisclosureSEC source: 0001214659-25-014856 · marketforms-71020.xml · nonDerivative · entry 2 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,525 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 3,000 | $31.15 | $93,450.00 |
DisclosureSEC source: 0001214659-25-014856 · marketforms-71020.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,042 F1 · shares: The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,875 | $32.19 | $189,098.63 |
DisclosureSEC source: 0001214659-25-014777 · marketforms-70992.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,042 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 918 | $25.96 | $23,834.95 |
DisclosureSEC source: 0001214659-25-012706 · marketforms-70340.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,917 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,449 | $38.15 | $93,419.55 |
DisclosureSEC source: 0001214659-25-010310 · marketforms-70077.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,569 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 936 | $29.75 | $27,843.19 |
DisclosureSEC source: 0001214659-25-008296 · marketforms-69628.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,018 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,542 | $34.97 | $88,887.13 |
DisclosureSEC source: 0001214659-25-005780 · marketforms-69137.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,954 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 918 | $44.18 | $40,554.49 |
DisclosureSEC source: 0001214659-25-003435 · marketforms-68343.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,496 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,886 | $43.26 | $254,646.02 |
DisclosureSEC source: 0001214659-25-000554 · marketforms-67833.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,096 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 26,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-020031 · marketforms-67496.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,982 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2024 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,160 | $44.61 | $185,556.80 |
DisclosureSEC source: 0001214659-24-018614 · marketforms-67292.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,237 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| November 06, 2024 Filed Nov 15, 2024 21:05 UTC Amendment | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,160 | $44.61 | $185,556.80 |
DisclosureSEC source: 0001214659-24-019254 · marketforms-67368.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,237 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 22:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-018498 · marketforms-67275.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,397 F1 · shares: Represents performance stock units for which target criteria was determined to have been met on November 4, 2024. 60% of the PSUs remain subject to time-based vesting and will vest on October 1,2025, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 856 | $41.81 | $35,791.07 |
DisclosureSEC source: 0001214659-24-017482 · marketforms-67154.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,397 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 842 | $48.91 | $41,184.75 |
DisclosureSEC source: 0001214659-24-012259 · marketforms-66532.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,602 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 09, 2024 Filed Apr 11, 2024 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 556 | $33.16 | $18,434.18 |
DisclosureSEC source: 0001214659-24-006630 · marketforms-65528.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,444 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-000566 · marketforms-63909.xml · nonDerivative · entry 2 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F2 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of January 8, 2024 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-000566 · marketforms-63909.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: 1/4th of the Total Number of Shares subject to the RSUs shall vest on the 1-year anniversary of the Vesting Commencement Date, and 1/16th of the total number of shares subject to the RSUs shall vest on each quarter anniversary (or on the last day of the on the month if no such day exists) thereafter, for a total vesting period of 48 months. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 16:15 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerCommon Stock | 33 | $2.60 | $85.80 |
DisclosureSEC source: 0001209191-23-056456 · doc4.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258 F1 · price: This sale was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2023. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 16:15 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerCommon Stock | 19 | $2.56 | $48.64 |
DisclosureSEC source: 0001209191-23-055740 · doc4.xml · nonDerivative · entry 2 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291 F2 · shares: Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 16:15 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerCommon Stock | 2,842 | $2.55 | $7,247.10 |
DisclosureSEC source: 0001209191-23-055740 · doc4.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310 F1 · price: This sale was effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2023. Read SEC document |
| August 17, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | SaleCommon Stock | 19 | $3.24 | $61.47 |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,152 F1 · shares: Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $3.23 to $3.24, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the shares of Common Stock sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerStock Option (Right to Buy) · Derivative | 824 | Not disclosed Strike: $1,051.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 8 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 824 shares Expires 2031-01-28 F9 · shares: On January 17, 2023, the Issuer effected a 1-for-20 reverse stock split of its Common Stock (the "Reverse Stock Split"). These securities reflect the Reverse Stock Split. F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: The Stock Option shall vest and become exercisable with respect to 16 quarterly installments commencing on February 15, 2021, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 824 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 7 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 824 Underlying: Common Stock · 824 shares Expires 2031-01-28 F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: The Stock Option shall vest and become exercisable with respect to 16 quarterly installments commencing on February 15, 2021, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerStock Option (Right to Buy) · Derivative | 82,500 | Not disclosed Strike: $11.58 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 6 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 82,500 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 5 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F6 · derivative.exercise_date: The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, provided, that, any unvested portion of the Stock Option shall vest and become exercisable upon attainment of a 360-day VWAP (volume weighted average price) of $20.00 for the Issuer's Common Stock, in either case, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | Disposition to issuerStock Option (Right to Buy) · Derivative | 82,500 | Not disclosed Strike: $11.58 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 4 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F5 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 82,500 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 3 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F4 · price: The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price. F3 · derivative.exercise_date: The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:10 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001209191-23-046243 · doc4.xml · derivative · entry 2 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2033-08-14 F3 · derivative.exercise_date: The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:05 UTC | Eargo, Inc. EAR · Entity 94112 | SaleCommon Stock | 19 | $4.69 | $89.11 |
DisclosureSEC source: 0001209191-23-030591 · doc4.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,171 F1 · shares: Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 16:12 UTC | Eargo, Inc. EAR · Entity 94112 | SaleCommon Stock | 21 | $7.37 | $154.77 |
DisclosureSEC source: 0001209191-23-011623 · doc4.xml · nonDerivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190 F1 · shares: Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F2 · balance_after: On January 17, 2023, the Issuer effected a 1-for-20 reverse stock split of its Common Stock (the "Reverse Stock Split"). These securities reflect the Reverse Stock Split. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:09 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-23-006789 · doc4.xml · derivative · entry 2 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F2 · derivative.exercise_date: The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:09 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-23-006789 · doc4.xml · derivative · entry 1 Laponis Adam · CIK 0001827198 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-01-31 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.